| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 06/22/2005 | EP1007533B1 Bioconjugates and delivery of bioactive agents |
| 06/22/2005 | EP0892644B1 In vivo gene transfer methods for wound healing |
| 06/22/2005 | EP0866874B2 Process for the preparation of materials with a high content of isomers of conjugated linoleic acid |
| 06/22/2005 | CN1630728A Buffer solution for electroporation and a method comprising the use of the same |
| 06/22/2005 | CN1630724A Compositions and methods for inhibiting expression of a target gene |
| 06/22/2005 | CN1630539A Multiple compartment bag assembly for dialysis fluid |
| 06/22/2005 | CN1630531A Composition comprising immunogenic microparticles |
| 06/22/2005 | CN1630530A Polyalkylene polymer compounds and uses thereof |
| 06/22/2005 | CN1630527A Methods and compositions for oxygen transport comprising a high oxygen affinity |
| 06/22/2005 | CN1630524A 非肠道顺铂乳剂 Cisplatin parenteral emulsion |
| 06/22/2005 | CN1630523A Compositions internal or relevant improvement |
| 06/22/2005 | CN1630521A Oral compositions and methods for prevention, reduction and treatment of radiation injury |
| 06/22/2005 | CN1630512A Pharmaceutical tablet |
| 06/22/2005 | CN1630511A Particulate compositions of eletriptan showing a sigmoidal pattern of controlled release |
| 06/22/2005 | CN1630510A Atorvastatin calcium in a pharmaceutical form, composition thereof, and pharmaceutical formulation comprising atorvastatin calcium |
| 06/22/2005 | CN1630509A Compositions and methods for delivering antibacterial, antifungal and antiviral ointments to the oral, nasal or vaginal cavity |
| 06/22/2005 | CN1630497A Drug delivery device |
| 06/22/2005 | CN1630494A Ophthalmic drug delivery device |
| 06/22/2005 | CN1629150A Paclitaxol predrug of biodegradable polymer and its synthesis method |
| 06/22/2005 | CN1628856A Film coated premix dissoluble in stomach and its preparation method |
| 06/22/2005 | CN1628855A Multifunctional depot type medicine carrier and preparation method thereof |
| 06/22/2005 | CN1628844A Method for extending in vivo half life of protein medicine by making red cell as carrier |
| 06/22/2005 | CN1628641A Enteric coated type thin membrane coated premixed agent and preparation method thereof |
| 06/22/2005 | CN1628637A Emulsion medicine carrying agent preparation technology |
| 06/22/2005 | CN1628636A Novel preparation with convertible fluidity |
| 06/22/2005 | CN1628634A Hydrophilic biological sticking gel pasting agent and preparation technique thereof |
| 06/22/2005 | CN1207323C Bivalent reaction water-soluble high molecular derivative and complex including the same |
| 06/22/2005 | CN1207210C Method for preparing micropowdered barium sulfate |
| 06/22/2005 | CN1206998C Composition and method for treating penile erectile dysfunction |
| 06/22/2005 | CN1206984C Pellets having a core coated with an antifungal and a polymer |
| 06/22/2005 | CN1206982C Stable protein: phospholipid compositions and methods |
| 06/22/2005 | CN1206976C Compositions and method for treating hair loss using C16-C20 aromatic tetrahydro prostaglandins |
| 06/21/2005 | US6908963 Coupling a polypeptide to end grouped modified polyether m |
| 06/21/2005 | US6908909 Liquid oral compositions comprising a calcium compound and an acidulant |
| 06/21/2005 | US6908903 Cluster clearing agents |
| 06/21/2005 | US6908900 Compositions and methods for enhanced pharmacological activity through oral and parenteral administration of compositions comprising polypeptide drug substances and other poorly absorbed active ingredients |
| 06/21/2005 | US6908897 At least one is a human or animal insulin analogue; coupled together with a diacid such as by reacting with suberic acid, bis(N-hydroxysuccinimidyl) ester |
| 06/21/2005 | US6908889 For shampoos/bath/shower gels for skin/nails/hair comprised of water soluble silicone |
| 06/21/2005 | US6908626 For poorly soluble drugs; micronizing |
| 06/21/2005 | US6908623 Compositions and methods for enhancing receptor-mediated cellular internalization |
| 06/21/2005 | US6908610 Stable granulocyte colony stimulating factor formulation containing one or more of lysine, histidine, arginine, aspartic acid, glutamic acid, threonine and asparagine; one or more hydrophobic amino acids; and methionine |
| 06/21/2005 | US6908609 Removing fluid from the intestinal tract of a host by directly delivering an effective amount of water-absorbent polymer to the intestinal tract |
| 06/21/2005 | CA2294788C Therapeutical system for transdermal delivery of levonorgestrel |
| 06/21/2005 | CA2150576C Injectable taxane derivatives based compositions |
| 06/21/2005 | CA2125579C Ulcer prevention treatment composition and method |
| 06/16/2005 | WO2005054446A2 Use of polysulphated alginate in cellular matrices |
| 06/16/2005 | WO2005054318A1 Stereocomplex hydrogels with tunable degradation times |
| 06/16/2005 | WO2005054303A2 Cyclodextrin dimers and derivatives thereof, methods for preparing them and their use, in particular, for solubilizing pharmacologically active substances |
| 06/16/2005 | WO2005054301A1 Crosslinked polysaccharide microparticles and process for producing the same |
| 06/16/2005 | WO2005054297A2 Cellulose interpolymers and method of oxidation |
| 06/16/2005 | WO2005054293A1 Rgd targeting moiety its porduction and use |
| 06/16/2005 | WO2005054279A1 Delivery peptides, their constructs with active agents and use |
| 06/16/2005 | WO2005053751A1 Animal model for experimental allergic neuritis and uses thereof |
| 06/16/2005 | WO2005053749A2 Thiol-cleavable linkage between polymer and ligand |
| 06/16/2005 | WO2005053748A1 Novel thickening agents having cationic units and method for preparing same |
| 06/16/2005 | WO2005053747A1 Composition containing peg for perfusion of an active agent in particular paracetamol |
| 06/16/2005 | WO2005053745A1 Erythropoietin solution formulation |
| 06/16/2005 | WO2005053738A1 Recombinant adenylate cyclase toxin of bordetella induces t cell responses against tumoral antigens |
| 06/16/2005 | WO2005053736A1 Oral vaccine, method for its preparation and use thereof |
| 06/16/2005 | WO2005053727A2 Pharmaceutical compositions for bioactive peptide agents |
| 06/16/2005 | WO2005053717A1 Stabilisation of viral microparticles |
| 06/16/2005 | WO2005053708A1 Loteprednol etabonate water base suspension formulation |
| 06/16/2005 | WO2005053691A2 Nicotine delivery product and method for producing it |
| 06/16/2005 | WO2005053684A1 Association of antimicrobial compounds with surfaces and polymers |
| 06/16/2005 | WO2005053666A1 Sprayable composition for the administration of vitamin d derivatives |
| 06/16/2005 | WO2005053660A2 Pharmaceutical compositions comprising danazol |
| 06/16/2005 | WO2005053650A1 Azithromycin dosage forms with reduced side effects |
| 06/16/2005 | WO2005053649A1 Biofunctionalized quantum dots for biological imaging |
| 06/16/2005 | WO2005053642A1 Drug delivery vehicles and uses thereof |
| 06/16/2005 | WO2005053637A2 Pharmaceutical spray formulation comprising a hypro fluor alkane amd an acylated cyclodextrin |
| 06/16/2005 | WO2005053599A1 Method for treatment of solid pharmaceutical preparation prior to printing and solid pharmaceutical preparation subjected to treatment prior to printing |
| 06/16/2005 | WO2005037928A3 Compounds for dual photodiagnosis and therapy |
| 06/16/2005 | WO2005030266A3 Optical imaging of colorectal cancer |
| 06/16/2005 | WO2005023181A3 Polymeric systems for controlled drug therapy |
| 06/16/2005 | WO2005014655A3 Conjugates of hydroxyalkyl starch and a protein |
| 06/16/2005 | WO2005008253A3 Stable compositions for measuring human natriuretic peptides |
| 06/16/2005 | WO2005003154A8 Compositions and methods for the diagnosis and treatment of tumor |
| 06/16/2005 | WO2005002554A3 A method of promoting sleep using topical administration of vasoactive agents |
| 06/16/2005 | WO2005000359A3 Chemically-modified human growth hormone conjugates |
| 06/16/2005 | WO2005000280A3 Dosage form comprising an exine coating of sporopollenin or derivatized sporopollenin |
| 06/16/2005 | WO2004112836A3 Ophthalmic compositions containing a synergistic combination of two polymers |
| 06/16/2005 | WO2004111192A3 Targeted delivery to legumain-expressing cells |
| 06/16/2005 | WO2004108165A3 Magnetic nanoparticles linked to a lingand |
| 06/16/2005 | WO2004096233A3 Nucleoside phosphonate conjugates |
| 06/16/2005 | WO2004050013A3 Material compositions and related systems and methods for treating cardiac conditions |
| 06/16/2005 | WO2004035006A3 Methods and compositions for immunization against hiv |
| 06/16/2005 | WO2004017904A3 Corticosteroid conjugates and uses thereof |
| 06/16/2005 | WO2003012072A3 Monoclonal antibodies to activated erbb family members and methods of use thereof |
| 06/16/2005 | US20050131363 Fiber substrate with odor absorbent |
| 06/16/2005 | US20050131200 Biocompatability; polyphosphoester/polyphosphoramidate linkages; improved gene delivery into muscles; DNA vaccines |
| 06/16/2005 | US20050131199 Hydrolysis of polyanhydride yielding active material |
| 06/16/2005 | US20050131079 Powder mixture with water; therapy for infections, inflammation of ears, throat |
| 06/16/2005 | US20050131071 Orodispersible pharmaceutical composition of agomelatine |
| 06/16/2005 | US20050131054 Test system for evaluating the compatibility of biologically active substances with copolymers |
| 06/16/2005 | US20050131051 2-3-disubstituted quinuclidiness as modulators of monoamine transporters and theraperutic and diagnostic methods based thereon |
| 06/16/2005 | US20050131027 Fine particle size pioglitazone |
| 06/16/2005 | US20050130952 Photodynamic therapy in selective cell inactivation in blood and treating immune dysfunction diseases |
| 06/16/2005 | US20050130947 6alpha, 9alpha-Difluoro-17alpha-((2-furanylcarbonyl)oxy)-11beta-hydroxy-16alpha-methyl-3-oxo-androsta-1,4-diene-17beta-carbothioic acid S-fluoromethyl ester completely dissolved in a liquified hydrofluoroalkane (HFA) gas as propellant; for asthma or chronic obstructive pulmonary disease (COPD) |
| 06/16/2005 | US20050130939 Substituted fullerene compositions and their use as antioxidants |
| 06/16/2005 | US20050130932 Viscoelastic preparations comprise 1.0-12.0 percent by weight of glycated chitosan in an aqueous solution; eye drops; bioresorbable; antibacterial properties |